News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
291 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37191)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53928)
2023 (42568)
2024 (38486)
2025 (17535)
Month
January (2946)
February (2976)
March (2714)
April (2913)
May (3639)
June (2347)
Day
2 (13)
3 (112)
4 (147)
5 (162)
6 (150)
7 (96)
9 (24)
10 (101)
11 (117)
12 (134)
13 (125)
14 (151)
17 (94)
18 (131)
19 (209)
20 (171)
21 (97)
24 (160)
25 (183)
26 (291)
27 (214)
28 (94)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
Day
2
3
4
5
6
7
9
10
11
12
13
14
17
18
19
20
21
24
25
26
27
28
Rare diseases
How SpringWorks Took Pfizer’s Rare Disease Ghost Drug and Got It to Patients
SpringWorks Therapeutics sprung out of Pfizer’s storeroom, when a rare disease advocacy group pushed to keep a program for neurofibromatosis alive. This method could work for “every rare disease under the sun,” advocates say.
February 26, 2025
·
5 min read
·
Annalee Armstrong
Pipeline
Kiniksa Axes Sjögren’s Program, AstraZeneca-Licensed Antibody in Cardio Pivot
Kiniksa will now focus its development efforts on the IL-1 blocker KPL-387, which it is testing for recurrent pericarditis with Phase II/III trials planned for mid-2025.
February 26, 2025
·
2 min read
·
Tristan Manalac
Editorial
The
BioSpace
Book Club Investigates the Biggest Deals of All Time
Our CEO accidentally started a book club. Now we’re all dreaming of mega pharma mergers.
February 26, 2025
·
3 min read
·
Annalee Armstrong
Cancer
AstraZeneca Posts Positive Phase III Results for Oral Breast Cancer Drug
In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments in terms of progression-free survival, according to AstraZeneca.
February 26, 2025
·
1 min read
·
Dan Samorodnitsky
Podcast
Trump’s Pharma Tariffs, Another GLP-1 Compounding Lawsuit, Bluebird’s Bailout, More
As FDA seeks to rehire some fired employees, Donald Trump threatens to enact tariffs on pharma companies unless they reshore manufacturing; another lawsuit hits the complex GLP-1 compounding space as Eli Lilly offers expanded Zepbound options; and struggling gene therapy biotech bluebird bio goes private in an attempt to stay solvent.
February 26, 2025
·
1 min read
·
Heather McKenzie
Neuroscience
Emalex Heads to FDA After Phase III Tourette Syndrome Win
Emalex is gearing up for a New Drug Application for ecopipam in Tourette syndrome later this year.
February 26, 2025
·
2 min read
·
Tristan Manalac
GLP-1
As Money Pours Into Weight Loss Drugs, Physicians Prioritize Efficacy, Access
As high prices and supply issues drive consumers to alternative markets for GLP-1s, physicians aren’t too interested in using these therapies to treat conditions like heart disease risk that have existing cheap standards of care.
February 26, 2025
·
5 min read
·
Annalee Armstrong
Rare diseases
How To Mine Biopharma’s IP Storeroom for Rare Disease Drugs, Just Like SpringWorks
SpringWorks Therapeutics is the perfect case study for rescuing a discontinued assets. It’s time to repeat the process for every rare disease, experts say.
February 26, 2025
·
5 min read
·
Annalee Armstrong
Government
Congress Re-Introduces EPIC Act to Remove IRA’s ‘Pill Penalty’
While many industry players and observers have high hopes for the EPIC Act, some say budgetary headwinds could make it difficult for the current administration to make meaningful repeals or amendments to the IRA.
February 26, 2025
·
2 min read
·
Tristan Manalac
Funding
Eikon Adds Nearly $351M to Conquer Phase III Development in Melanoma
Eikon’s lead candidate, EIK1001, is being tested for advanced melanoma. The candidate is currently in late-stage development, which the biotech will fund using Wednesday’s series D raise.
February 26, 2025
·
1 min read
·
Tristan Manalac
1 of 30
Next